Bristol-Myers Squibb (BMY) said Monday that its phase 3 Odyssey-HCM trial, which evaluated Camzyos in adults with symptomatic New York Heart Association class II-III non-obstructive hypertrophic cardiomyopathy, did not meet its dual primary endpoints.
The trial failed to show a statistically significant difference from placebo in changes from baseline to week 48 in both the Kansas City Cardiomyopathy Questionnaire - Clinical Summary Score and peak oxygen consumption.
No new safety signals were observed, the company added.
Shares of Bristol-Myers Squibb were down 2% in after-hours trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.